ravulizumab-话题@MedSci - williamhill asia

#ravulizumab#

7篇内容 | 1015人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2206732, encodeId=a7e32206e32bf, content=<a href='/topic/show?id=581e26889ea' target=_blank style='color:#2F92EE;'>#依库珠单抗#</a> <a href='/topic/show?id=a9de9930377' target=_blank style='color:#2F92EE;'>#非典型溶血性尿毒症综合征#</a> <a href='/topic/show?id=6e566913df' target=_blank style='color:#2F92EE;'>#ERA#</a> <a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>, objectTitle=ERA 2024：从依库珠单抗转用ravulizumab的非典型溶血性尿毒症综合征患者的特征和安全性：真实世界研究, objectType=article, longId=827655, objectId=506e82e65561, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240526/1716714369948_8624274.png, objectUrl=/article/show_article.do?id=506e82e65561, replyNumber=0, likeNumber=50, createdTime=2024-05-26, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=506e82e65561, moduleTitle=ERA 2024：从依库珠单抗转用ravulizumab的非典型溶血性尿毒症综合征患者的特征和安全性：真实世界研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=506e82e65561)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2124109, encodeId=e03f212410934, content=长效<a href='/topic/show?id=c59110582225' target=_blank style='color:#2F92EE;'>#补体C5蛋白抑制剂#</a><a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>能降低<a href='/topic/show?id=ea7810582164' target=_blank style='color:#2F92EE;'>#AQP4#</a>抗体阳性的<a href='/topic/show?id=e30d90e23cf' target=_blank style='color:#2F92EE;'>#视神经脊髓炎谱系疾病#</a>患者的复发风险降低98.6%, objectTitle=长效补体C5蛋白抑制剂ravulizumab能降低AQP4抗体阳性的NMOSD患者的复发风险降低98.6%, objectType=article, longId=745354, objectId=db70e45354bb, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221027/e11ac154aeb74a5c861b133a828adb92.jpg, objectUrl=/article/show_article.do?id=db70e45354bb, replyNumber=0, likeNumber=82, createdTime=2023-04-06, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=db70e45354bb, moduleTitle=长效补体C5蛋白抑制剂ravulizumab能降低AQP4抗体阳性的NMOSD患者的复发风险降低98.6%, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=db70e45354bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685343, encodeId=42d41685343d4, content=<a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>, objectTitle=NEJM Evid：Ravulizumab用于抗AchR抗体阳性重症肌无力效果持久有效（CHAMPION MG研究）, objectType=article, longId=726131, objectId=557fe26131ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=557fe26131ca, replyNumber=0, likeNumber=56, createdTime=2022-08-19, rootId=0, userName=liuyg0237, userId=5df828134847, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=557fe26131ca, moduleTitle=NEJM Evid：Ravulizumab用于抗AchR抗体阳性重症肌无力效果持久有效（CHAMPION MG研究）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=557fe26131ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685341, encodeId=89291685341b0, content=<a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>, objectTitle=ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价, objectType=article, longId=193433, objectId=e611193433d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e611193433d4, replyNumber=0, likeNumber=74, createdTime=2021-04-05, rootId=0, userName=liuyg0237, userId=5df828134847, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e611193433d4, moduleTitle=ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=e611193433d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685342, encodeId=76b9168534227, content=<a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>, objectTitle=日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）, objectType=article, longId=201254, objectId=80e12012542c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80e12012542c, replyNumber=0, likeNumber=56, createdTime=2020-11-20, rootId=0, userName=liuyg0237, userId=5df828134847, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80e12012542c, moduleTitle=日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=80e12012542c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685340, encodeId=fd1b168534007, content=<a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>, objectTitle=C5抑制剂Ultomiris（ravulizumab-cwvz）治疗重症COVID-19患者的临床试验：即将开展, objectType=article, longId=192701, objectId=46b6192e01ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46b6192e01ae, replyNumber=0, likeNumber=67, createdTime=2020-07-13, rootId=0, userName=liuyg0237, userId=5df828134847, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46b6192e01ae, moduleTitle=C5抑制剂Ultomiris（ravulizumab-cwvz）治疗重症COVID-19患者的临床试验：即将开展, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=46b6192e01ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685338, encodeId=62ea168533840, content=<a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>, objectTitle=Blood：用Ravulizumab替代依库丽单抗治疗PNH疗效不变, objectType=article, longId=155208, objectId=52fd155208b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=52fd155208b4, replyNumber=0, likeNumber=65, createdTime=2019-05-04, rootId=0, userName=liuyg0237, userId=5df828134847, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=52fd155208b4, moduleTitle=Blood：用Ravulizumab替代依库丽单抗治疗PNH疗效不变, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=52fd155208b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1685339, encodeId=0cfb168533913, content=<a href='/topic/show?id=d17e1515814' target=_blank style='color:#2F92EE;'>#ravulizumab#</a>, objectTitle=Blood：Ravulizumab和依库丽单抗治疗阵发性睡眠性血红蛋白尿的效果对比, objectType=article, longId=155209, objectId=d4bf1552095c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4bf1552095c, replyNumber=0, likeNumber=104, createdTime=2018-12-25, rootId=0, userName=liuyg0237, userId=5df828134847, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4bf1552095c, moduleTitle=Blood：Ravulizumab和依库丽单抗治疗阵发性睡眠性血红蛋白尿的效果对比, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d4bf1552095c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

ravulizumab

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#依库珠单抗# #非典型溶血性尿毒症综合征# #ERA# #ravulizumab#

ERA 2024：从依库珠单抗转用ravulizumab的非典型溶血性尿毒症综合征患者的特征和安全性：真实世界研究

2024-05-26发表于上海

侠胆医心 (审核中...)

前往app查看评论内容

长效#补体C5蛋白抑制剂##ravulizumab#能降低#AQP4#抗体阳性的#视神经脊髓炎谱系疾病#患者的复发风险降低98.6%

长效补体C5蛋白抑制剂ravulizumab能降低AQP4抗体阳性的NMOSD患者的复发风险降低98.6%

2023-04-06发表于上海

liuyg0237 (审核中...)

前往app查看评论内容

#ravulizumab#

NEJM Evid：Ravulizumab用于抗AchR抗体阳性重症肌无力效果持久有效（CHAMPION MG研究）

2022-08-19

liuyg0237 (审核中...)

前往app查看评论内容

#ravulizumab#

ULTOMIRIS（ravulizumab）治疗非典型溶血性尿毒症综合征（aHUS）：CHMP给予积极评价

2021-04-05

liuyg0237 (审核中...)

前往app查看评论内容

#ravulizumab#

日本厚生劳动省批准ravulizumab治疗成人和儿童非典型溶血性尿毒症综合征（aHUS）

2020-11-20

liuyg0237 (审核中...)

前往app查看评论内容

#ravulizumab#

C5抑制剂Ultomiris（ravulizumab-cwvz）治疗重症COVID-19患者的临床试验：即将开展

2020-07-13

liuyg0237 (审核中...)

前往app查看评论内容

#ravulizumab#

Blood：用Ravulizumab替代依库丽单抗治疗PNH疗效不变

2019-05-04

liuyg0237 (审核中...)

前往app查看评论内容

#ravulizumab#

Blood：Ravulizumab和依库丽单抗治疗阵发性睡眠性血红蛋白尿的效果对比

2018-12-25

科室
- - 订阅+
  - 更多科室
工具
服务